Table 3.
Relative number of patients using resources at least once, stratified by gender (n = 2095).
| Resource consumption |
|||
|---|---|---|---|
| Men n = 567 |
Women n = 1528 |
||
| % | % | p-value* | |
| Total costs | 98.2% | 98.8% | 0.357 |
| Direct costs | 96.6% | 97.7% | 0.099 |
| Direct medical costs | 96.6% | 97.6% | 0.120 |
| Inpatient care | 15.2% | 14.2% | 0.358 |
| Day admissions | 5.8% | 6.5% | 0.724 |
| Ambulant consultations | 93.3% | 94.4% | 0.175 |
| Examinations | 53.4% | 50.1% | 0.426 |
| Complementary medicine | 4.4% | 7.9% | 0.007 |
| Acupuncture | 3.2% | 4.2% | 0.216 |
| Medical consumables | 13.6% | 22.1% | <0.001 |
| Professional care | 5.8% | 11.1% | <0.001 |
| Non-prescription medication | 46.9% | 53.6% | 0.005 |
| Direct non-medical costs | 20.5% | 29.8% | <0.001 |
| Investments | 3.2% | 4.1% | 0.420 |
| Informal care | 19.2% | 28.9% | <0.001 |
| Indirect costs | 59.1% | 50.4% | <0.001 |
| Sick leave | 23.3% | 21.3% | 0.099 |
| Presenteeism | 53.8% | 45.5% | <0.001 |
| Disability pension | 10.1% | 10.6% | 0.686 |
Adjusted for age, baseline EDSS, disease activity (PIRA, RAW, RWW, DAF, others), study affiliation (DMT group) and follow-up time.
DAF, disease activity free; DMT, disease-modifying treatments; EDSS, Expanded Disability Status Scale; PIRA, progression independent of relapse activity; RAW, relapse-associated worsening; RWW, relapse without worsening.